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Abstract
Background: Activation of wild-type p53 in response to genotoxic stress occurs through different mechanisms
including protein conformation, posttranslational modifications, and nuclear localization, leading to DNA binding to
sequence-specific promoters. Zinc ion plays a crucial role in stabilizing p53/DNA binding to induce canonical target
genes. Mutant p53 proteins undergo protein misfolding that can be counteracted by zinc. However, whether zinc
supplementation might have a beneficial antitumor effect in wild-type p53-carrying cells in combination with
drugs, has not been addressed so far.
Methods: In this study we compared the effect of two antitumor treatments: on the one hand wild-type p53-carrying
colon cancer cells were treated with low and high doses of chemotherapeutic agent Adriamycin and, on the other
hand, Adriamycin was used in combination with ZnCl2. Biochemical and molecular analyses were applied to evaluate
p53 activity and biological outcomes in this setting. Finally, the effect of the different combination treatments were
applied to assess tumor growth in vivo in tumor xenografts.
Results: We found that low-dose Adriamycin did not induce p53 activation in wtp53-carrying colon cancer cells, unless
in combination with ZnCl2. Mechanistically, ZnCl2 was a key determinant in inducing wtp53/DNA binding and
transactivation of target genes in response to low-dose Adriamycin that used alone did not achieve such effects.
Finally, in vivo studies, in a model of wtp53 colon cancer xenograft, show that low-dose Adriamycin did not induce
tumor regression unless in combination with ZnCl2 that activated endogenous wtp53.
Conclusions: These results provide evidence that ZnCl2 might be a valuable adjuvant in chemotherapeutic regimens
of colorectal cancer harboring wild-type p53, able to both activate p53 and reduce the amount of drugs for antitumor
purposes.
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Background
Colorectal cancer (CRC) is still the third most common
cancer and the second most common cause of cancer-
related death in Western countries [1]. Despite recent im-
provement in treating CRC, the response rate still remains
low [2]. Of the patients, 30 % have advanced disease at
presentation, either locally or at distant sites, so surgery is
rarely a sufficient treatment. Consequently, chemotherapy
alone or in combination with other agents remains the only
viable therapeutic option, although the response of cancer
cells to genotoxic therapies may be critically impaired by
genetic alterations or drug-resistant mechanisms [3, 4].
The tumor suppressor p53 is a transcription factor that,
upon DNA damage, is activated to induce target genes in-
volved in either cancer cell growth arrest or apoptosis and
its proper activation is central for efficient response to
therapies aiming at tumor eradication [5]. Activation of
wild-type (wt) p53 occurs in response to genotoxic stress
essentially through posttranslational modifications, such
as acetylation and phosphorylation, resulting in protein
stabilization (by escape from proteasome-mediated deg-
radation) and nuclear localization leading to binding to
sequence-specific promoters of target genes as final out-
come of its function as transcription factor [6]. TP53 in-
cludes one zinc ion (Zn2+) as an important cofactor for
the proper protein folding to efficiently bind to the DNA
[7]. Seminal studies in the past years showed that changes
in intracellular zinc levels may inactivate wtp53 function
by inducing the protein to switch to a `mutant-like' con-
formation with loss of DNA-binding capacity [8–10].
Interestingly, mutant p53 proteins are prone to the loss of
the Zn2+ bound to the DNA binding domain (DBD) with
the consequence of protein unfolding and aggregation
with loss of wild-type activity [11]. Taking advantage of
those findings, in recent studies we addressed the issue of
mutant p53 reactivation by ZnCl2 or zinc complex for an-
ticancer purposes. The combination of drug treatment
and zinc restores p53 oncosuppressive activity, thus redu-
cing the chemoresistance of mutant p53-carrying cancer
cells with increased cancer cell death in vitro and inhib-
ition of tumor growth in vivo [12–16]. These findings
opened the way to the drug development of mutant p53
reactivators exploiting the effect of zinc [17, 18]. To the
best of our knowledge, however, the effect of zinc supple-
mentation on drug response of wtp53-carrying cancer
cells has not been evaluated yet and, in this study, we
aimed to address this theme.
We found that zinc supplementation to wtp53-carrying
colon cancer cells markedly improved p53 stability/activity
in response to low-dose Adriamycin (ADR) that used
alone did not show p53 stabilization nor efficient cytotoxic
effect. Mechanistically, we found that zinc co-treatment
with low-dose ADR allowed more efficient wtp53 nuclear
accumulation and DNA binding for transactivation of
target genes, compared to drug treatment alone. An
in vivo study of tumor growth in a model of wtp53 colon
cancer xenograft showed that zinc treatment increased
low-dose drug response with marked impairment of
tumor growth. This effect was due, at least in part, to
zinc-induced wtp53 activation, in agreement with the
in vitro data. These findings demonstrate the beneficial ef-
fect of zinc supplementation in wtp53-carrying colorectal
cancer cells both improving wtp53 activity and reducing




All animals were handled in strict accordance with good
animal practice as defined by the relevant national and/
or local animal welfare bodies, and in accordance with
the Italian and European legislation. All experimental
protocol were approved by the Ethical Committee for
animal research of the National Cancer Institute Regina
Elena, in Rome, Italy, and by the Italian Ministry of
Health, and performed in accordance with the Italian
and European legislation.
Cell culture and treatments
RKO and HCT116 human colon cancer cell lines were
maintained in DMEM (Life Technology-Invitrogen), sup-
plemented with 10 % heat-inactivated fetal bovine serum
(FBS), 100 units/mL penicillin, 100 μg/mL streptomycin
(Life Technology-Invitrogen), and 2 mmol/LL-glutamine
in a humidified atmosphere with 5 % CO2 and 95 % air at
37 °C. For treatments, zinc chloride (ZnCl2) (SIGMA) was
added to the culture medium to a final concentration of
100 μM for the indicated time points; and Adriamycin
(ADR) was added to the culture medium at different con-
centrations, ranging between 2 and 0.1 μg/ml (3.4 and
0.17 μM, respectively). The ADR dose of 0.1 μg/ml and
1 μg/ml were considered, respectively, low and high, for
the purpose of the study.
Cell viability
Subconfluent cells were plated in triplicate in 60 mm
Petri dishes and 24 h later treated with ADR or ZnCl2
alone or in combination for the indicated time points.
Both floating and adherent cells were collected and cell
viability was determined by Trypan blue exclusion by
direct counting with a haemocytometer, as reported [19].
The percentage of cell viability, as blue/total cells, was
assayed by scoring 200 cells per well three times.
Western immunoblotting and immunoprecipitation
Cells were harvested from cultured dishes and total cell
extracts were prepared by incubating at 4 °C for 30 min
in lysis buffer [50 mM Tris–HCl (pH 7.5), 50 mM NaCl,
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5 mM EDTA, 150 mM KCl, 1 mM DTT, 1 % Nonidet P-
40] and a mix of protease inhibitors (Roche Diagnostic).
Cell lysates were spun at 15000 g for 15 min to remove
debris and collect the supernatant (total cell extracts).
Protein concentration was then determined using BCA
Protein Assay Kit (Biorad). Nuclear extracts were pre-
pared essentially as described [20]. Briefly, cells were
suspended in hypotonic buffer [10 mM HEPES, pH 7.9,
10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA] and placed
on ice for 15 min. Nonidet P-40 was added to a final
concentration of 0.5 %. Cells were spun top speed for
30 s and the supernatant (cytoplasmic fraction) was dis-
charged. The remaining pellet was washed with hypotonic
buffer, resuspended in lysis buffer as above and spun at
15000 g for 15 min to remove debris and collect the
supernatant (nuclear fraction). Total or nuclear cell lysates
(10 to 40 μg protein/lane) were resolved by 9–18 % SDS-
polyacrylamide gel electrophoresis. For immunoprecipita-
tion analyses, total cell extracts were immunoprecipitated
with anti-p53 antibodies (Ab-DO1, Santa Cruz Biotech-
nology) preadsorbed to protein G–agarose (Pierce) for 2 h
at 4 °C. Immunocomplexes were collected by centrifuga-
tion, separated by 9 % SDS–PAGE. Proteins were trans-
ferred to a polyvinylidene difluoride (PVDF) membrane
(Millipore). The blotted membranes were blocked with
5 % skim milk for 1 h and then were incubated with the
following primary antibodies: monoclonal anti-poly(ADP-
ribose) polymerase cleaved form (PARP, BD Pharmingen,
CA, USA), monoclonal anti-p53 (Ab-DO1), polyclonal
antip53 (FL393), polyclonal anti-p21, monoclonal anti-
MDM2 (Ab1, Santa Cruz), rabbit polyclonal anti-lamin A
(all from Santa Cruz Biotechnology), rabbit polyclonal
phospho-Ser46 and phospho-Ser15 (Cell Signalling and
Santa Cruz), purified mouse anti-phospho-Histone H2AX
(Ser139) (Millipore, clone JBW301; kindly provided by S.
Soddu, Regina Elena National cancer Institute, Rome,
Italy) and monoclonal anti-β-actin (Calbiochem). The
immunoreactive bands were visualized by enhanced che-
moluminescence (ECL; Amersham) using horseradish
peroxidase-conjugated IgG secondary antibodies (BioRad).
RNA extraction and semi-quantitative reverse transcrip-
tion (RT)-PCR analysis
Cells and tumors were harvested in TRIzol Reagent (Invi-
trogen) and total RNA was isolated following the manu-
facturer’s instructions. Semi-quantitative RT-PCR was
performed essentially as previously described [12]. Briefly,
The first strand cDNA was synthesized from 2 μg of total
RNA with MuLV reverse transcriptase kit (Applied Bio-
systems). Semi-quantitative Reverse-Transcribed (RT)-
PCR was carried out by using Hot-Master Taq polymerase
(Eppendorf) with 2 μl cDNA reaction and genes specific
oligonucleotides under conditions of linear amplification.
PCR products were resolved on 2 % agarose gels and
visualized by ethidium bromide staining using UV light.
The housekeeping 28S gene, used as internal standard,
was amplified from the same cDNA reaction mixture.
Densitometric analysis was applied to quantify mRNA
levels compared to control gene expression.
Chromatin immunoprecipitation (ChIP)
ChIP analysis was carried out essentially as previously
described [20]. Briefly, protein complexes were cross-
linked to DNA in living cells by adding formaldehyde
directly to the cell culture medium at 1 % final concen-
tration for 10 min at room temperature and then inacti-
vated by the addition of 125 mM glycine. Chromatin
extracts containing DNA fragments with an average size
of 500 bp were incubated overnight at 4 °C with skim
milk, shaking using polyclonal anti-p53 antibody (FL393,
Santa Cruz Biotechnology). Before use, protein G (Pierce)
was blocked with 1 μg/μl sheared herring sperm DNA and
1 μg/μl BSA for 3 h at 4 °C and then incubated with chro-
matin and antibody for 2 h at 4 °C. PCR was performed
with Hot-Master Taq (Eppendorf) using 2 μl of immuno-
precipitated DNA and promoter-specific primers span-
ning p53 binding sites. Immunoprecipitation with non-
specific immunoglobulins (IgG, Santa Cruz Biotechnol-
ogy) was performed as negative controls. The amount of
precipitated chromatin measured in each PCR was nor-
malized with the amount of chromatin present in the in-
put of each immunoprecipitation. PCR products were
resolved on 2 % agarose gel and visualized with ethidium
bromide staining using UV light.
In vivo tumor growth
In vivo experiments were performed essentially as de-
scribed [12]. Six-week-old CD-1 nude (nu/nu) mice
(Charles River Laboratories) were used for in vivo stud-
ies. They were housed in specific pathogen-free condi-
tions and fed standard cow pellets and water ad libitum.
Studies were performed in accordance with the National
Cancer Institute Regina Elena standard guidelines for
animal care and all experimental protocol were approved
by the Ethical Committee for animal research of the Na-
tional Cancer Institute Regina Elena, in Rome, Italy, and
by the Italian Ministry of Health, and performed in ac-
cordance with the Italian and European legislation. Solid
tumors were obtained by injecting i.m. on the flank of
each mouse 4x106 viable RKO cells suspended in 0.1 mL
PBS. The mice were examined every day after injection
until tumors reached approximately 300 mm3 volume
(about 7 days from injection). Mice were then random-
ized in four groups (6–8 mice/group) as follow: 1) PBS
(Mock), 2) ADR, 3) ZnCl2, 4) ADR plus ZnCl2. At day 7,
mice were injected with ADR (1 mg/kg body weight) i.p.;
subsequently, ZnCl2 (10 mg zinc/kg body weight) was
administrated once daily by oral administration, over the
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course of about two weeks. Tumor dimensions were
measured every other day and their volumes were calcu-
lated from caliper measurements of two orthogonal diam-
eters (x and y, larger and smaller diameters, respectively)
by using the formula, volume = xy2/2. The antitumor ef-
fect of the combination treatment, ZnCl2 + ADR, was
evaluated by comparing the relative tumor size with tu-
mors treated with ADR only or ZnCl2 only. The experi-
ment was repeated twice with similar results.
Statistical analyses
All experiment unless differently indicated were per-
formed at least three times. Results are expressed as values
of mean ± standard deviation (SD). Paired t-test (two-
tailed) was used for assessing the statistical significance of
the differences between treatment groups (P = 0.05).
Results
ZnCl2 increases p53 protein levels in the presence of
low-dose ADR
To evaluate the in vitro effect of zinc supplementation on
wtp53 activation in response to drug, RKO and HCT116
colon cancer cells, carrying wtp53, were treated with the
chemotherapeutic drug ADR that has been widely used
for treatment of a broad spectrum of cancers [21], al-
though it can induce harmful dose-dependent effects in
different sites [22, 23]. We compared two different treat-
ment strategies: on the one hand colon cancer cells were
incubated with increasing concentrations of ADR, ranging
between 2 and 0.1 μg/ml (3.4 and 0.17 μM, respectively)
for 24 h; on the other hand, dose–response ADR incuba-
tion was carried out in the presence of ZnCl2. We first
analysed p53 protein levels by western immunoblotting of
total cell extracts. We found that ADR alone induced p53
expression starting at 0.5 μg/ml in RKO cells (Fig. 1a) and
at 1 μg/ml in HCT116 cells (Fig. 1b); interestingly, ZnCl2
induced p53 stabilization in combination with ADR at
dose as low as 0.1 μg/ml, in both cell lines (Fig. 1a, b).
Intracellular amount of p53 is regulated by phosphoryl-
ation at different sites within the protein to enhance sta-
bility and activity as transcription factor [6], therefore, we
investigated p53 phosphorylation in this setting. We found
that p53 was phosphorylated in serine (Ser) 15 and 46 by
ADR alone at 1 μg/ml dose, while ZnCl2 co-treatment in-
duced p53 phosphorylation at 0.1 μg/ml ADR, and like-
wise protein stabilization (Fig. 1c). To evaluate whether
p53 stabilization following ZnCl2 co-treatment with low-
dose ADR could depend on increased DNA damage
Fig. 1 ZnCl2 increases the low-dose ADR-induced p53 stabilization in colon cancer cells. (a) RKO and (b) HCT116, plated under the same confluence
condition, were treated with increasing doses (0.1 to 2 μg/ml) of ADR in the presence or absence of ZnCl2 (100 μM), for 24 h. Equal amounts of total
cell lysates were subjected to immunoblot analysis for the detection of the expression levels of p53, γH2AX, and PARP (cleaved form). The
samples derive from the same experiment and gels/blots were processed in parallel. (c) The phosphorylation of p53 at Ser15 and Ser46 was
detected in HCT116 treated with ADR (0.1-1-2 μg/ml) in the presence or absence of ZnCl2 (100 μM) for 24 h, by western blotting. Anti-β-actin
was used as protein loading control. The samples derive from the same experiment and gels/blots were processed in parallel. The gels have
been run under the same experimental conditions and one representative set of blot from three independent experiments, all generating
similar results, is shown here. (d) HCT116 cells were treated with ADR (0.2 μg/ml) and ZnCl2 (100 μM) for 24 h. After treatments, total cell
extracts were immunoprecipitated with anti-p53 antibody. Western blot analysis was performed with anti-p53 and anti-MDM2 antibodies. IP:
immunoprecipitation. IB: immunoblotting
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response (DDR), we analysed histone H2AX phosphoryl-
ation. The phosphorylation of the subtype of histone
H2A, called H2AX, in the position of Ser139 producing
γH2AX, occurs in response to formation of double strand
brakes (DSB) and the analysis of γH2AX expression can
be used to detect the genotoxic effect of different antican-
cer agents [24]. Western blot analysis shows that γH2AX
phosphorylation did not significantly change between the
two treatments (i.e., ADR alone or in combination with
ZnCl2) (Fig. 1a), suggesting that ZnCl2 was not increasing
DNA damage and that, consequently, was not the mech-
anism responsible for higher p53 stabilization. The phos-
phorylation of p53 at N-terminal Ser15 and Ser46 has
been shown to contribute to p53 stability by preventing
the p53 negative regulator MDM2 from degrading it
[25, 26]. We then investigated the p53/MDM2 inter-
action. We treated HCT116 cells with low-dose ADR
alone or in combination with ZnCl2 and, after treat-
ments, total cell extracts were immunoprecipitated with
anti-p53 antibody. Normalization of total cell extracts
was applied in order to have approximately the same
amount of p53 immunoprecipitated in the ADR alone
and ADR/ZnCl2 combination. As shown in Fig. 1d,
MDM2 binding to p53 following ADR treatment was
significantly reduced by ZnCl2 co-treatment (P = 0.003).
This effect is in line with previous studies showing that
zinc neutralizes the ubiquitine ligase activity of MDM2
restoring p53 activity [27, 28].
Time-course experiment shows that while 0.1 μg/ml
ADR alone did not induce p53 stabilization during the
24 h treatment, ZnCl2 co-treatment increased p53 protein
levels beginning at 4 h post-treatment (Fig. 2a); parallel to
p53 stabilization, the downstream effector p21 WAF1/
Cip1 (p21) was also upregulated (Fig. 2a), suggestive of
p53 activation. ZnCl2 treatment alone did not induce p53
levels (Fig. 2b), indicative of zinc effectiveness for p53 acti-
vation specifically in combination with drug. For PARP ex-
pression in Fig. 1b see below. Finally, we examined p53
nuclear localization, which, along with p53 stability is at
the basis of p53 transcriptional activity [6]. Western blot-
ting of nuclear extracts show that low-dose ADR (0.1 μg/
ml) did not efficiently induce p53 nuclear accumulation
unless in combination with ZnCl2, in both cell lines
(Fig. 2c). Altogether, these results demonstrate that zinc
supplementation could improve wtp53 stability, nuclear
accumulation, and activation following co-treatment with
low-dose ADR that used alone did not show such effects,
at least in our experimental conditions.
ZnCl2 improves the DNA binding as well as transcriptional
activity of p53 in the presence of low-dose ADR
We then evaluated whether p53 stabilization matched
the induction of its transcriptional activity. To this aim,
in vivo p53-DNA binding activity was analysed by
chromatin immunoprecipitation (ChIP) technique. RKO
and HCT116 cells were treated with low (0.1 μg/ml) and
high dose (1 μg/ml) ADR for 16 h in the presence or ab-
sence of ZnCl2 and endogenous p53 immunoprecipi-
tated with polyclonal anti-p53 antibody. The amount of
Fig. 2 ZnCl2 induces p53 nuclear accumulation and activation in the
presence of low-dose ADR. (a) HCT116 were treated with low-dose
ADR (0.1 μg/ml) in the presence or absence of ZnCl2 (100 μM), for
4-8-16-24 h. Equal amounts of total cell lysates were subjected to
immunoblot analysis for the detection of the expression levels of
p53 and p21. Anti-β-actin was used as protein loading control. The
samples derive from the same experiment and gels/blots were
processed in parallel. One representative set of blot from three
independent experiments, all generating similar results, is shown
here. (b) RKO were treated with ZnCl2 (100 μM), for 4-8-16-24 h
and the expression levels of p53 was detected by western blotting.
A positive control for p53 expression in the same cells, is included
(ADR 2 μg/ml for 16 h). Anti-β-actin was used as protein loading
control. (c) RKO and HCT116 were treated with low-dose ADR
(0.1 μg/ml) in the presence or absence of ZnCl2 (100 μM), 8 h.
Equal amounts of nuclear extracts were separated by SDS-PAGE
and p53 levels detected by western blotting. Anti-Lamin A was
used as protein loading control. The gels have been run under the
same experimental conditions and one representative set of blot
from three independent experiments, all generating similar results,
is shown here
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co-precipitated p53-binding elements in target pro-
moters was determined by PCR. The results show that
low-dose ADR did not recruit p53 onto canonical target
promoters, such as Puma, p53AIP1, MDM2, and p21,
unless in combination with ZnCl2, in both HCT116 (left
panel) and RKO cells (right panel) (Fig. 3a, compare
lanes 2 with lanes 4). As a control we used the high dose
ADR (1 μg/ml) that was efficient to induce p53 binding
to target promoters (Fig. 3a, compare lanes 3 with lanes
2) and such recruitment was not further increased by
ZnCl2 (Fig. 3a, compare lanes 3 with lanes 6), suggesting
that p53 was fully activated by the high dose ADR even
in the absence of ZnCl2. As additional control, RKO
cells were also treated with ZnCl2 alone that did not
Fig. 3 ZnCl2 induces p53/DNA binding and transactivation activities in the presence of low-dose ADR. a HCT116 (left panel) and RKO cells (right panel)
(4x106) were plated in 150 mm dish and the day after treated with ADR (0.1-1 μg/ml) and ZnCl2 (100 μM) for 16 h before being assayed for ChIP
analysis with anti-p53 antibody. PCR analyses were performed on the immunoprecipitated DNA using primers specific for p53 target genes. A sample
representing linear amplification of the total chromatin (Input) was included as control. Additional controls included immunoprecipitation performed
with nonspecific immunoglobulins (IP: IgG). One representative experiment, out of two independent experiments generating similar results, is shown
here. b HCT116 and RKO cells were treated with ADR (0.1-0.2-0.5-1 μg/ml) in the presence or absence of ZnCl2 (100 μM) for 16 h before total mRNAs
were reverse transcribed for analysis of p53 apoptotic target genes (Noxa and Puma) expression, using RT-PCR. 28S was used as a control for efficiency
of RNA extraction and transcription. One representative experiment, out of two independent experiments with similar results, is shown here.
c Densitometric analysis of gene expression as shown in (b) in HCT116 (left panel) and RKO (right panel) cells was plotted as expression ratio
to 28S. The data represent the mean of two independent experiments ± S.D. Paired student’s t test was used for the statistical analysis of the
normalized gene expression (Gene/28S ratios) at different ADR doses, with or without ZnCl2 (*: P < 0.01)
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allow p53 binding to DNA promoters (Fig. 3a, right
panel, lane 6). Next, in vivo analyses of mRNA levels
upon dose–response ADR treatment, with or without
ZnCl2, shows that ADR alone induced the upregulation of
p53 apoptotic target genes (here, Noxa and Puma) starting
at 0.5 and 1 μg/ml, respectively for RKO and HCT116
cells, while ZnCl2 co-treatment induced p53 target gene
expression starting at 0.1 μg/ml ADR (Fig. 3b), that is, by
lowering the ADR dose 5 to 10 times, depending on cell
sensitivity. Densitometric analyses show that the induction
of these genes was basically always higher in the presence
of ZnCl2, and the statistical significance was indeed
reached at three ADR dose levels (0.1, 0.2 and 0.5 μg/ml)
and for both cell lines, while this difference faded at ADR
1 μg/ml (Fig. 3c), suggesting that functionally speaking
these two experimental conditions become almost undis-
tinguishable when higher doses of ADR were used (with
some cell line-specific features). Additionally, it is interest-
ing to note that for both cell lines, ADR 0.5 μg/ml with
ZnCl2 was about like ADR 1 μg/ml without ZnCl2 (or
even stronger in HCT116); this outcome seems to be
promising in the perspective to optimize this treatment
for a possible clinical application.
These results demonstrate that zinc supplementation
improves wtp53/DNA binding and transcriptional activ-
ities in response to low-dose ADR with respect to ADR
alone.
ZnCl2 improves the low-dose ADR-induced tumor regression
in vivo
To measure the biological effect of zinc supplementation
to low-dose ADR we first analysed cell viability by trypan
blue staining. We found that the negligible effect of low-
dose ADR on cell death was significantly increased by
ZnCl2 (Fig. 4a). We next measured induction of apoptosis
by western blot analysis of PARP cleavage. We found that
ADR alone induced PARP cleavage starting at 1 μg/ml in
HCT116 cells (Fig. 1b), concomitant to p53 expression;
interestingly, ZnCl2 co-treatment induced PARP cleavage
at ADR concentration as low as 0.1 μg/ml (Fig. 1b). Simi-
lar results were observed in RKO cells (data not shown).
To evaluate whether the administration of ZnCl2 is able to
improve the efficacy of ADR on tumor growth in vivo, we
generated tumor xenografts in athymic nude mice by
injecting RKO cells. We previously reported that ZnCl2
could enhance the antitumor effect of ADR used at
10 mg/Kg body weight in RKO xenografts [29], here, we
attempted to perform similar experiments by lowering ten
times the amount of ADR used (that is, 1 mg/kg body
weight); the aim was to test in vivo the results obtained
here in the in vitro experiments. Groups of CD-1 nude
mice were treated with ADR and ZnCl2 alone or in com-
bination and tumor growth analysed for about two weeks
after the beginning of treatments. Although tumors
treated with low-dose ADR alone displayed significant re-
duction of tumor volume over the course of 2 weeks treat-
ment (ADR versus Mock or ZnCl2: *P = 0.05, day 12),
(Fig. 4b), a significant greater delay of tumor growth was
observed in the combination of ZnCl2 and low-dose ADR
group (ADR/ZnCl2 versus ADR: **P = 0.01) (Fig. 4b). The
weight of the mice was also measured twice a week to
highlight possible toxicity and the change of mouse body
weight was plotted in Fig. 4c. We observed a slight reduc-
tion of body weight during the treatments which was
comparable between the ADR and ADR/ZnCl2 groups
(Fig. 4c). Tumors were harvested by day 12 after the be-
ginning of treatments and mRNA extracted for p53 target
gene expression by RT-PCR and densitometric analyses.
The results show that p53 apoptotic target genes, includ-
ing Puma and Bax, were slightly induced by low-dose
ADR and markedly increased by ZnCl2 supplementation
(Fig. 4d), as evidenced by densitometric analyses of the
normalized gene expression (Fig. 4e). Taken together,
these data show that in vivo ZnCl2 supplementation mark-
edly improved tumor regression in response to low-dose
ADR in part due to increasing wtp53 activity, in agree-
ment with the in vitro data.
Discussion
The results of this study highlight the beneficial effect
of zinc supplementation in anticancer therapeutic regi-
mens of wtp53-carrying colon cancer cells. Interest-
ingly, zinc-induced p53 activation allowed reducing of
about ten times the amount of ADR used with still effi-
cient cytotoxic antitumor effect. The final biological
outcome was improved tumor response to low-dose
ADR in vitro and in vivo.
P53 activation is a big matter in cancer field involving the
discovery of the mechanisms of p53 activation/inactivation
and the development of drug targeted molecules for the
achievement of efficient response to therapies [5, 17]. The
p53 oncosuppressor activities, such as cell cycle arrest,
apoptosis, or senescence, are achieved through the control
of p53-mediated transcription of target genes involved in
cell-cycle arrest, senescence, (e.g., p21/WAF1/Cip1) or
apoptosis (e.g., Puma, Noxa, Bax, p53AIP1etc.) [30]. Acti-
vation of p53 can be modulated at several levels such as
increase of the p53 protein stabilization with subsequent
protein phosphorylation, switch to a folded conformation
suitable for binding to canonical DNA promoters, and ef-
ficient nuclear translocation for transactivation function
[31]. The p53 protein is kept at a low concentration
through rapid degradation by its natural inhibitor MDM2
[32] and the stabilization of a functional p53 is reached
under precise circumstances such as DNA damage,
deprivation of growth factors, oncogene activation, etc.
[5]. Here we found that ZnCl2 supplementation induced
p53 stabilization even in the absence of genotoxic damage
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(as shown by lack of γH2AX phosphorylation) and, subse-
quently, p53 activity in combination with low-dose ADR
that used alone did not achieve such effects. Mechanistic-
ally, zinc supplementation reduced the p53 binding to
MDM2, in agreement with previous studies showing that
zinc inhibits proteasome-dependent protein degradation
[33] and neutralizes the ubiquitine ligase activity of p53
natural inhibitor MDM2 [27]. This finding was further
supported here by phosphorylation at N-terminal Ser15
and Ser46 (Fig. 1c) that has been shown to contribute
to p53 stability by preventing MDM2 from degrading it
[25, 26]. To the best or our knowledge this is the first
Fig. 4 Zinc supplementation improves the antitumor effects of low-dose ADR. a RKO cells (2x105) were plated at subconfluence in 60-mm Petri dish
and the day after treated with ADR (0.1 μg/ml) and ZnCl2 (100 μM) alone or in combination for 24 h. Cell death was measured by trypan blue exclusion
assay and expressed as percentage ± SD of three independent experiments performed in duplicate. Paired student’s t test was used for the statistical
analysis of cell death percentages in the presence of ADR alone or in combination with ZnCl2 (*: P < 0.01). b RKO cells were injected i.m. into the right
flanks of nude mice. Drug and ZnCl2 treatments were started when the tumors became palpable, and the size of tumors was measured twice a week
and plotted as the average tumor volumes versus number of days post-treatment. Paired student’s t test was used for the statistical analysis of tumor
volumes in the presence of ADR alone (black square) or in combination with ZnCl2 (red square) (*: P < 0.01). c Percentage change of mouse body
weight measured throughout the experiment. d Tumors were explanted at day 12 after treatments and used for total mRNA extraction and RT-PCR
analysis of p53 target genes. 28S was used as a control for efficiency of RNA extraction and transcription. RNA samples from explanted tumors show
respectively one Mock tumor, two ADR-treated tumors and two ADR/ZnCl2-treated tumors. One representative experiment, out of two independent
experiments generating similar results, is shown here. e Densitometric analysis of gene expression was plotted as expression ratio to 28S. The data
represent the mean of two independent experiments ± S.D. Paired student’s t test was used for the statistical analysis of the normalized gene
expression (Gene/28S ratios) at different ADR doses, with or without ZnCl2 (*: P < 0.01)
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time that ZnCl2 was employed in wtp53-carrying can-
cer cells to test wtp53 activation in combination with
low-dose anticancer drugs. Indeed, recent studies also
from us, taking advantage of seminal data of the past
years, exploited the effect of zinc ion to target the misfold-
ing of mutant p53 proteins for reactivation of wtp53 onco-
suppressive activity [11–16]. Although p53 mutation is
usually a late event in colon cancer progression [34], its
protein inactivation may be achieved by different mecha-
nisms. Chelation experiments carried out in 1993 first
demonstrated that p53 is a zinc-dependent metalloprotein
[35] and that zinc is necessary for p53 site-specific DNA
binding and proper transcriptional activation [7, 11].
Many studies report that cellular zinc deficiency can be
achieved by different conditions such as age, insufficient
dietetic intake [36], or by alteration of metallothioneins
(MTs). MT is a class of cysteine-rich, metal binding pro-
teins that controls the intracellular distribution of zinc,
acts as a potent chelator to remove zinc from wtp53 and
modulate p53 conformation and transcriptional activity
[8, 10]. Increased expression of MT can be found in vari-
ous human tumors including colon, and some evidence
also supports a role for MT in acquired drug-resistance
[37] and in inhibition of wtp53 activity [13, 38]. These
findings suggest that zinc might be a valuable molecule to
activate wtp53 in cancer cells also in the absence of TP53
gene mutations. Several studies have shown that p53 re-
constitution results in regression of various types of tu-
mors [39, 40] while normal tissues are not significantly
affected by genetic p53 re-establishment [41, 42]. By con-
trast, it appears that the environment of tumor cells sup-
ports p53-mediated growth suppression, resulting in a
more drastic response induced by p53.
An interesting issue highlighted by our results is the
possibility to reduce the amount of chemotherapeutic
drugs while maintaining efficient cytotoxic effects. Indeed,
the use of some broad spectrum chemotherapeutic drugs
such as Adriamycin has been limited in oncologic practice
by its overwhelming and harmful dose-dependent effects
leading to irreversible and often fatal drug-induced con-
gestive heart failure [22, 23]. The possibility to reduce the
amount of ADR is therefore an important goal and the re-
sults that we have shown here suggest that the combin-
ation with zinc supplementation could be explored in
clinical practice to reduce the amount of ADR in the at-
tempt to improve the treatment of CRC as well as patient
survival. Indeed, the fact that ZnCl2 in combination with
low-dose ADR did not negatively affect the good health of
animals in the in vivo experiment (as shown by body
weight analysis), supports the use of such combination
treatment in order to reduce toxic effects in sites different
than the tumor. More in-depth studies will be needed to
better clarify this topic. In addition, whether the reduction
of the amount of drugs might be reached by ZnCl2 in
combination with chemotherapeutic agents different than
ADR needs to be addressed. Another issue to keep in
mind is that there are many zinc-associated enzymes and
transcription factors in cells and that the zinc supplemen-
tation might affect many biological processes in vivo. In
this regard, we previously described the positive effect of
zinc in modulating several pathways involved in chemore-
sistance, angiogenesis, tumor migration and immuno-
logical response [14, 43–46], and that zinc complex, orally
administrated, preferentially localizes into the tumor site
[43], supporting the positive effect of such supplementa-
tion in anticancer therapies.
In conclusion, the present study provides insight into
the clinically translatable approach of a combination
strategy using low-dose ADR and ZnCl2 in wtp53-
carrying cancer cells with the double result of improving
wtp53 activity and reducing the dose of chemotherapy
for cytotoxic antitumor purposes.
Abbreviations
ADR: Adriamycin; ChIP: chromatin immunoprecipitation; DBD: DNA binding
domain; DDR: DNA damage response; DSB: double strand brakes; RT-PCR: reverse
transcription polymerase chain reaction; SD: standard deviation; wt p53: wild-type
p53; ZnCl2: zinc chloride.
Competing interests
The authors declare that they have no competing interests.
Authors‘ contributions
GDO designed the study. AG, VU, SB, VDO, FM, and GB performed
experiments. GDO, FM, and GB analysed data. GDO wrote the paper. All
authors read and approved the final manuscript.
Acknowledgments
This study was supported by Grant from Italian Association for Cancer
Research (AIRC). We thank Maria Pia Gentileschi for technical assistance.
Author details
1Department of Medical, Oral and Biotechnological Sciences, University “G.
d’Annunzio”, 66013 Chieti, Italy. 2Translational Research Department, Regina
Elena National Cancer Institute, 00158 Rome, Italy. 3Institute of Cell Biology
and Neurobiology, National Research Council of Italy (CNR), Roma, Italy.
4Department of Surgical Sciences, Sapienza University, 00100 Rome, Italy.
5Laboratory of Medical Physics and Expert Systems, Regina Elena National
Cancer Institute, 00158 Rome, Italy.
Received: 14 July 2015 Accepted: 12 August 2015
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer.
2010;127:2893–917.
2. Allen WL, Coyle VM, Johnston PG. Predicting the outcome of chemotherapy
for colorectal cancer. Curr Opin Pharmacol. 2006;6:332–6.
3. Amini A, Masoumi-Moghaddam S, Ehteda A, Lawson Morris D. Bromelain
and N-acetylcysteine inhibit proliferation and survival of gastrointestinal
cancer cells in vitro: significance of combination therapy. J Exp Clin Cancer
Res. 2014;33:92.
4. Niero EL, Rocha-Sales B, Lauand C, Cortez BA, de Souza MM, Rezende-Teixeira
P, et al. The multiple facets of drug resistance: one history, different
approaches. J Exp Clin Cancer Res. 2014;33:37.
5. Vousden KH, Lane DP. P53 in health and disease. Nat Rev Mol Cell Biol.
2007;8:275–83.
6. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the
molecular basis for p53 regulation. Curr Opin Cell Biol. 2003;15:164–71.
Garufi et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:87 Page 9 of 10
7. Cho Y, Gorina PD. Crystal structure of a p53 tumor suppressor-DNA
complex: Understanding tumorigenic mutations. Science. 1994;265:346–55.
8. Hainaut P, Milner J. A structural role for metal ions in the “wild-type”
conformation of the tumor suppressor protein p53. Cancer Res.
1993;53:1739–42.
9. Verhaegh GW, Parat MO, Richard MJ, Hainaut P. Modulation of p53
conformation and DNA-binding activity by intracellular chelation of zinc.
Mol Carcinog. 1998;21:205–14.
10. Méplan C, Richard MJ, Hainaut P. Metalloregulation of the tumor suppressor
p53 zinc mediates the renaturation of p53 after exposure to metal chelators
in vitro and in intact cells. Oncogene. 2000;19:5227–36.
11. Loh SN. The missing zinc: p53 misfolding and cancer. Metallomics.
2010;2:442–9.
12. Puca R, Nardinocchi L, Gal H, Rechavi G, AMariglio N, Domany E, et al.
Reversible Dysfunction of Wild-Type p53 following Homeodomain-Interacting
Protein Kinase-2 knockdown. Cancer Res. 2008;68:3707–14.
13. Puca R, Nardinocchi L, Bossi G, Sacchi A, Rechavi G, Givol D, et al. Restoring
wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein
and zinc. Exp Cell Res. 2009;315:67–75.
14. Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, et al.
Restoring p53 active conformation by zinc increases the response of
mutant p53 tumor cells to anticancer drugs. Cell Cycle. 2011;10:1679–89.
15. Garufi A, Trisciuoglio D, Porru M, Leonetti C, Stoppacciaro A, D’Orazi V, et al.
A fluoreascent curcumin-based Zn(II)-complex reactivates mutant (R175H
and R273H) p53 in cancer cells. J Exp Clin Cancer Res. 2013;32:72.
16. Garufi A, Pucci D, D’Orazi V, Cirone M, Bossi G, Avantaggiati ML, et al.
Degradation of mutant p53H175 protein by Zn(II) through autophagy. Cell
Death Dis. 2014;5, e1271.
17. Yu X, Narayanan S, Vazquez A, Carpizo DR. Small molecule compound
targeting the p53 pathways: are we finally making progress? Apoptosis.
2014;19:1055–68.
18. Blanden AR, Yu X, Wolfe AJ, Gilleran JA, Augeri DJ, O'Dell RS, et al. Synthetic
metallochaperone ZMC1 rescues mutant p53 conformation by transporting
zinc into cells as an ionophore. Mol Pharmacol. 2015;87:825–31.
19. Garufi A, D'Orazi V, Arbiser JL, D'Orazi G. Gentian violet induces p53
transactivation in cancer cells. Int J Oncol. 2014;44:1084–90.
20. Di Stefano V, Soddu S, Sacchi A, D'Orazi G. HIPK2 contributes to PCAF-mediated
p53 acetylation and selective transactivation of p21Waf1 after non-apoptotic
DNA damage. Oncogene. 2005;24:5431–42.
21. Millan A, Huerta S. Apoptosis-inducing factor and colon cancer. J Surg Res.
2009;151:163–70.
22. Minow RA, Benjamin RS, Lee E, Gottllieb JA. Adriamycin cardiomyopathy-risk
factors. Cancer. 1977;39:1397–402.
23. Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy.
Cardiology. 2010;115:155–62.
24. Podhorecka M, Skladanowski A, Bozko P. H2AX phosphorylation: its role in
DNA damage response and cancer therapy. J Nucl Acids. 2010;920161. doi:
10.4061/2010/920161
25. Shieh S-Y, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation
of p53 alleviates inhibition by MDM2. Cell. 1997;9:325–34.
26. Di Stefano V, Blandino G, Sacchi A, Soddu S, D'Orazi G. HIPK2 neutralizes
MDM2 inhibition rescuing p53 transcriptional activity and apoptotic
function. Oncogene. 2004;23:5185–92.
27. Nardinocchi L, Puca R, Givol D, D’Orazi G. Counteracting MDM2-induced
HIPK2 downregulation restores HIPK2/p53 apoptotic signaling in cancer
cells. FEBS Lett. 2010;584:4253–8.
28. Nardinocchi L, Puca R, D’Orazi G. HIF-1a antagonizes p53-mediated
apoptosis by triggering HIPK2 degradation. Aging-US. 2011;3:33–43.
29. Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D’Orazi G. Targeting
hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2
and p53 activity and suppressing HIF-1a. Plos One. 2009;4, e6819.
30. Schuler M, Green DR. Transcription, apoptosis and p53: catch-22. Trends
Genet. 2005;2:182–7.
31. Liang S-H, Clarke MF. Regulation of p53 localization. Eur J Biochem.
2001;268:2779–83.
32. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation
of p53. Nature. 1997;387:296–9.
33. Kim I, Kim CH, Kim JH, Lee J, Chen ZA, Lee MG, et al. Pyrrolidine
dithiocarbamate and zinc inhibit proteasome-dependent proteolysis. Exp
Cell Res. 2004;298:229–38.
34. Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat. 2003;21:271–6.
35. Pavletich NP, Chambers KA, Pabo CO. The DNA-binding domain of p53
contains the four conserved regions and the major mutation hot spots.
Genes Dev. 1993;7:2556–64.
36. Brown KH, Rivera JA, Bhutta Z, Gibson RS, King JC, Lönnerdal B, et al.
International Zinc Nutrition Consultative Group (IZiNCG) technical
document #1. Assessment of the risk of zinc deficiency in populations and
options for its control. Food Nutr Bull. 2004;25:S299–203.
37. Cherian MG, Jayasurya A, Bay B-H. Metallothioneins in human tumors and
potential roles in carcinogenesis. Mut Res. 2003;533:201–9.
38. Hable N, Hamidouche Z, Girault I, Patino-Garcia A, Lecanda F, Marie PJ, et al.
Zinc chelation: a metallothionein 2A’s mechanism of action involved in
osteosarcoma cell death and chemotherapy resistance. Cell Death Dis.
2013;4, e874.
39. Martins CP, Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic
efficacy of p53 restoration in tumors. Cell. 2006;127:1223–34.
40. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al.
Restoration of p53 function leads to tumor regression in vivo. Nature.
2007;445:661–5.
41. D'Orazi G, Marchetti A, Crescenzi M, Coen S, Sacchi A, Soddu S. Exogenous
wt-p53 protein is active in transformed cells but not in their non-transformed
counterparts: implications for cancer gene therapy without tumor targeting. J
Gene Med. 2000;2:11–21.
42. Bossi G, Mazzaro G, Porrello A, Crescenzi M, Soddu S, Sacchi A. Wild-type
p53 gene transfer is not detrimental to normal cells in vivo: implications for
tumor gene therapy. Oncogene. 2004;23:418–25.
43. Nardinocchi L, Pantisano V, Puca R, Porru M, Aiello A, Grasselli A, et al. Zinc
downregulates HIF-1 alpha and inhibits its activity in tumor cells in vitro and
in vivo. Plos One. 2010;5, e15048.
44. Sheffer M, Simon AJ, Jacob-Hirsch J, Rechavi G, Domany E, Givol D, et al.
Genome-wide analysis discloses reversal of the hypoxia-induced changes of
gene expression in colon cancer cells by zinc supplementation. Oncotarget.
2011;2:1191–202.
45. Margalit E, Simon AJ, Yakubov E, Puca R, Yosepovich A, Avivi C, et al. Zinc
supplementation augments in vivo antitumor effect of chemotherapy by
restoring p53 function. Int J Cancer. 2012;131:E562–8.
46. Cirone M, Garufi A, Di Renzo L, Granato M, Faggioni A, D'Orazi G. Zinc
supplementation is required for the cytotoxic and immunogenic effects of
chemotherapy in chemoresistant p53-functionally deficient cells.
Oncoimmunol. 2013;2, e26198.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Garufi et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:87 Page 10 of 10
